Researchers reported that structural variations in Acinetobacter capsules influence both antibiotic resistance and host immune recognition. The study dissected how capsule composition alters drug penetration and immune activation, linking capsule phenotypes to survival in hospital environments and patient outcomes. Findings highlight capsule biology as a targetable determinant of pathogenicity in multidrug‑resistant Acinetobacter baumannii. The work suggests new avenues for therapeutics—either disrupting capsule assembly or exploiting capsule signatures to improve vaccine or antibody design—at a time when Acinetobacter remains a major cause of in‑hospital infections and limited treatment options.